Clinical Trial Search

Phase 2 N=12 A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease

Multiple Myeloma · Non-hodgkin's Lymphoma · Hodgkin's Disease

Primary: Number of Patients Achieving the CD34+ Hematopoietic Stem Cell (HSC) Mobilization Target of ≧2.5×1000000 Cells/kg — 7; 5 participants

GPCR Therapeutics, Inc. Results Jan 2015 0.0% serious AE View details

N/A N=92 Respiratory Dysregulation and Breathing Training in Anxious Outpatients

Anxiety

Primary: Episodic Anxiety Scale — 8.1; 9.0; 14.3 units on a scale

US Department of Veterans Affairs Results Jan 2015 0.0% serious AE View details

Phase 2 N=30 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

Chronic Hepatitis C Virus Infection

Primary: Mean Maximal Change From Baseline in Hepatitis C Virus Ribonucleic Acid (HCV RNA) Levels During ABT-333 Monotherapy Treatment — -1.01; -0.78; -0.68; -0.26 log10 IU/mL…

AbbVie (prior sponsor, Abbott) Results Jan 2015 0.0% serious AE View details

Phase 2 N=21 Akt Inhibitor MK2206 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Recurrent Squamous Cell Carcinoma of the Nasopharynx · Stage IV Squamous Cell Carcinoma of the Nasopharynx

Primary: Proportion of Patients Alive and Progression-free — 9; 12 participants

National Cancer Institute (NCI) Results Jan 2015 47.6% serious AE View details

Phase 2 N=74 A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072

Hepatitis C · HCV · Chronic Hepatitis C Infection

Primary: Maximal Change From Baseline in Hepatitis C Virus Ribonucleic Acid (HCV RNA) Levels During ABT-450/r, ABT-333, or ABT-072 Monotherapy Treatment — -4.07; -3.91; -4.11…

AbbVie (prior sponsor, Abbott) Results Jan 2015 2.7% serious AE View details

Phase 2 N=11 A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV)

Hepatitis C · HCV · Chronic Hepatitis C Infection

Primary: Percentage of Participants With Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Suppressed Below the Lower Limit of Quantitation (LLOQ) From Week 4 Through Week 12 — 100…

AbbVie (prior sponsor, Abbott) Results Jan 2015 0.0% serious AE View details

Phase 2 N=50 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-333 and Ribavirin (RBV) in Treatment-Naïve and Non-responder Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

Chronic Hepatitis C Infection · Hepatitis C · Hepatitis C Virus

Primary: Percentage of Participants With Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Suppressed Below the Lower Limit of Detection (LLOD) From Week 4 Through Week 12 — 89.5…

AbbVie (prior sponsor, Abbott) Results Jan 2015 0.0% serious AE View details

Phase 2 N=42 Oral Uridine for Treatment of Bipolar Depression in Adolescents

Bipolar Disorder

Primary: Mean Scores in Children's Depression Rating Scale (CDRS-R), Assessed Before and After 6 Week Uridine Treatment — 60.00; 21.29; 33.83; 20 Units on a scale

University of Utah Results Jan 2015 5.0% serious AE View details